Particularly in hypertension accompanied by dyslipidemia, RAS inhibitors may exhibit anti-inflammatory, antifibrotic, and antioxidant effects in the kidneys by inhibiting the Gq signaling pathway through the AT1-LOX-1 complex in renal tubular cells and fibroblasts. This evidence concerns the gene OLR1 and hypertensive disorder.